Skip to main content
Lotus Pharm logo

Lotus Pharm — Investor Relations & Filings

Ticker · 1795 ISIN · TW0001795003 LEI · 984500BEECDBC04KP716 TW Manufacturing
Open in API
Filings indexed 2,730 across all filing types
Latest filing 2026-04-09 Director's Dealing
Country TW Taiwan
Listing TW 1795

About Lotus Pharm

http://www.lotuspharm.com.tw

Lotus Pharmaceutical Co., Ltd. is a global specialty organization focused on the development, manufacturing, and commercialization of high-barrier generic and specialty medicines. The company specializes in complex generics, with a primary focus on oncology, immunology, and addiction treatment. Its portfolio includes technically demanding products such as Lenalidomide, Suboxone, Nintedanib, and Vinorelbine, as well as an advancing pipeline of biosimilars and 505(b)(2) oncology candidates. Utilizing an integrated R&D and manufacturing platform, the company executes a "2x2" growth strategy centered on dual market expansion and product diversification. Its commercial footprint spans over 90 markets globally, maintaining a strong presence in the Asia-Pacific region and the United States. The company prioritizes high technical entry barriers and cost-effective therapeutic solutions to improve global patient access to essential medications.

Recent filings

Filing Released Lang Actions
115年03月內部人持股異動(事後)
Director's Dealing Classification · 85% confidence The document is a detailed table of directors’ and senior management’s shareholdings (including spouses/minors), showing opening positions, month‐end holdings, and any increases or decreases. This is clearly an insiders’ shareholding disclosure rather than an earnings or management report or a simple publication notice. It fits the definition of a Director’s Dealing/Insider Transaction report (DIRS).
2026-04-09 Chinese
115年03月董事會成員及持股
Director's Dealing Classification · 90% confidence The document is a periodic disclosure of shareholdings by company insiders (directors, independent directors, managers) provided to the public information observatory. It lists insiders’ current holdings, pledged shares, and family holdings, which aligns with reporting of personal share transactions/holdings by directors and executives. Therefore, it is best classified as a Director’s Dealing (insider holdings disclosure).
2026-04-09 Chinese
公告本公司Nintedanib Capsules 100 mg及150 mg學名藥 獲得美國FDA核可並取得學名藥藥證
Regulatory Filings Classification · 85% confidence The document is an official material information disclosure from a listed Taiwanese company (美時) on the Market Observation Post System (公開資訊觀測站), announcing FDA approval of a generic drug. It is not an annual/interim report, earnings release, management change, or financial supplement, but a general regulatory announcement of a corporate event. This falls under the fallback category Regulatory Filings (RNS).
2026-04-03 Chinese
本公司董事會通過子公司Lotus International Pte.Ltd.取得Sandoz AG於菲律賓之所有業務 並簽訂資產購買協議
M&A Activity Classification · 91% confidence The document is a company announcement filed on Taiwan’s Market Observation Post System (公開資訊觀測站) reporting that the parent has approved its subsidiary’s acquisition of all business operations of Sandoz AG in the Philippines via an asset purchase agreement. This is clearly an M&A transaction announcement rather than a share issue or financing update. Therefore, it should be classified under M&A Activity (TAR).
2026-04-02 Chinese
代重要子公司Alvogen Korea Holdings Ltd.公告董事當選 名單
Board/Management Information Classification · 94% confidence The document is a regulatory filing on the Taiwan MOPS system by listed company 美時 (code 1795). The title states it is announcing the elected board members of its important subsidiary Alvogen Korea Holdings Ltd. It details director resignations, appointments dates, reasons, and profiles. This is clearly an announcement of changes in the company’s board of directors, matching the “Board/Management Information” category.
2026-03-31 Chinese
代重要子公司Alvogen Korea Holdings Ltd.公告2026年股東 常會重要決議事項
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a formal announcement of the resolutions passed at the 2026 shareholders’ meeting of a subsidiary (items include dividend distribution, charter amendments, approval of financial statements, director elections, and remuneration approval). This is exactly a declaration of voting results at a general meeting, matching the “Declaration of Voting Results & Voting Rights Announcements” category (DVA).
2026-03-31 Chinese

Browse filings by year

14 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.